Neoadjuvant Therapy for Resectable Biliary Tract Cancer: A Meta-Analysis of Surgical and Survival Outcomes

Neoadjuvant Therapy for Resectable Biliary Tract Cancer: A Meta-Analysis of Surgical and Survival Outcomes

Cholangiocarcinoma remains a challenging malignancy to treat, even when diagnosed at a potentially resectable stage. Surgical resection offers the possibility of cure, but recurrence remains common, including among patients who undergo margin-negative (R0) resection. Despite advances in surgery and perioperative management, long-term survival outcomes remain limited.

Adjuvant capecitabine is an established postoperative treatment for resected biliary tract cancer, based on the BILCAP trial. However, some patients are unable to receive postoperative systemic therapy because of surgical complications, delayed recovery, or early recurrence.

These limitations have increased interest in neoadjuvant treatment, which may allow earlier delivery of systemic therapy, address occult micrometastatic disease, and help assess tumor behavior before surgery. Nevertheless, the role of this approach in patients with resectable biliary tract cancer remains uncertain.

A systematic review and meta-analysis appearing in the December 2026 issue of Cancer Treatment Reviews (Volume 151) examined the available prospective evidence on neoadjuvant systemic therapy, focusing on treatment feasibility, surgical outcomes, radiological response, and survival.

The study, titled “Survival outcomes following neoadjuvant therapy for resectable cholangiocarcinoma: a systematic review and reconstructed individual patient data meta-analysis,” was conducted by Giovanni Trovato, Laura Chiofalo, Cinzia Bagalà, Francesca Belenghi, Kristian Shtembari, Daniele Lavacchi, Lorenzo Antonuzzo, Giampaolo Tortora, Daniele Rossini, and Lisa Salvatore.

Study Design and Methods

The investigators conducted a systematic literature search of PubMed/MEDLINE, Embase, and CENTRAL through April 30, 2026, identifying prospective phase II and III trials evaluating neoadjuvant systemic therapy followed by planned surgical resection in biliary tract cancer.

Six prospective trials, comprising seven active neoadjuvant treatment arms and a total of 280 patients, were included in the final analysis. These consisted of two randomized phase III trials and four phase II trials, including one randomized phase II study. The included studies were ZSAB-neoGOLP, GAIN, NEO-GAP, DEBATE, KHBO1201, and the phase II study by Matsuyama and colleagues.

The trials evaluated different preoperative treatment approaches, including chemotherapy alone, intensified chemotherapy combinations, chemo-immunotherapy, and chemo-immunotherapy combined with targeted therapy. Patient populations also varied. Some trials focused specifically on high-risk resectable intrahepatic cholangiocarcinoma, while others included broader biliary tract cancer populations, including gallbladder and ampullary malignancies. The Matsuyama study enrolled patients with borderline resectable perihilar cholangiocarcinoma.

For the randomized phase III studies, only patients assigned to the neoadjuvant treatment arms were included in the pooled analysis. Therefore, the meta-analysis primarily assessed outcomes following neoadjuvant treatment rather than directly comparing this strategy with upfront surgery.

The investigators assessed neoadjuvant-to-surgery completion, curative-intent resection, objective response rate (ORR), and R0 resection rate. Survival outcomes were evaluated using reconstructed individual patient data obtained from published Kaplan–Meier curves, with random-effects models used to generate pooled estimates. Overall survival (OS) was measured from treatment initiation.

Biliary Tract Cancer

Treatment Completion and Surgical Outcomes

The analysis showed that neoadjuvant systemic therapy was feasible in selected patients, although not all patients who started treatment ultimately underwent curative-intent surgery.

Across the seven neoadjuvant treatment arms, the pooled neoadjuvant-to-surgery completion rate was 79.0% (95% CI, 63.0–89.0%). This endpoint represented patients who completed their planned preoperative treatment and subsequently underwent surgical exploration. The pooled curative-intent resection rate was 71.0% (95% CI, 54.0–84.0%), indicating that a substantial proportion of patients did not ultimately proceed to curative-intent surgery.

The pooled objective response rate was 21.2% (95% CI, 9.0–42.3%), based on six neoadjuvant treatment arms reporting radiological response according to RECIST criteria. Importantly, the intention-to-treat R0 resection rate was 63.6% (95% CI, 44.7–79.0%), reflecting the proportion of patients who achieved microscopically margin-negative resection among those who initially entered the neoadjuvant treatment strategy.

Considerable heterogeneity was observed across studies, particularly for treatment completion, curative-intent resection, radiological response, and R0 resection. Nevertheless, sensitivity analyses showed that the overall estimates remained broadly consistent when individual treatment arms were excluded.

Exploratory analyses according to treatment class found numerical differences in response and surgical outcomes. The chemo-immunotherapy-targeted therapy category had an estimated ORR of 54.5% and an R0 resection rate of 95.5%.

However, these estimates were derived from the ZSAB-neoGOLP treatment arm and should not be interpreted as evidence that this regimen is superior to other neoadjuvant approaches. Differences in patient characteristics, tumor biology, and treatment strategies limit comparisons between treatment classes.

Survival Outcomes

The investigators reconstructed individual patient data from published Kaplan–Meier curves to estimate overall survival and recurrence-related outcomes.

Pooled OS estimates were:

  • 12-month OS: 84.0% (95% CI, 78.0–89.0%).
  • 24-month OS: 63.0% (95% CI, 55.0–71.0%).
  • 36-month OS: 51.0% (95% CI, 44.0–59.0%).
  • 60-month OS: 38.0% (95% CI, 24.0–53.0%), based on only two treatment arms.

For recurrence-related survival, the investigators combined disease-free survival (DFS), progression-free survival (PFS), and event-free survival (EFS) because of the limited number of available studies. The pooled estimates for this composite endpoint were:

  • 12 months: 60.0% (95% CI, 51.0–69.0%).
  • 24 months: 41.0% (95% CI, 33.0–50.0%).
  • 36 months: 37.0% (95% CI, 30.0–45.0%).

At 60 months, a recurrence-related survival estimate of 33.5% (95% CI, 27.2–39.9%) was available from a single treatment arm, and no meta-analysis was performed for this time point. The investigators also explored whether survival differed between neoadjuvant-only regimens and perioperative strategies that incorporated planned postoperative systemic therapy.

No statistically significant differences were identified at the evaluated 12- and 24-month survival landmarks. For example, 24-month OS was 54.0% (95% CI, 36.8–70.4%) with neoadjuvant-only treatment and 62.1% (95% CI, 51.1–72.1%) with perioperative treatment (p=0.498).

Similarly, the corresponding 24-month recurrence-related survival estimates were 40.0% and 35.2%, respectively (p=0.537). These exploratory comparisons were based on a limited number of heterogeneous studies and do not establish whether postoperative systemic therapy provides additional benefit following neoadjuvant treatment.

Clinical Implications and Limitations

The findings provide an overview of surgical feasibility and survival outcomes associated with neoadjuvant systemic therapy in prospective biliary tract cancer trials. One important aspect of the analysis is its intention-to-treat assessment of surgical outcomes. Although the pooled curative-intent resection rate was 71.0% and the intention-to-treat R0 resection rate was 63.6%, these findings also highlight that a substantial proportion of patients starting neoadjuvant treatment did not ultimately undergo curative-intent surgery.

The analysis has several limitations. Only six prospective trials were available, and the studies differed considerably in anatomical tumor location, baseline risk characteristics, resectability criteria, and treatment regimens. Additionally, the investigators combined DFS, PFS, and EFS into a composite recurrence-related endpoint despite differences in their definitions and starting points. Survival outcomes were reconstructed from published Kaplan–Meier curves rather than obtained from original patient-level datasets.

Treatment-class comparisons were exploratory and subject to confounding, while the small number of studies limited the interpretation of subgroup findings. Although the primary estimates remained consistent across sensitivity analyses, the pooled results cannot establish whether neoadjuvant therapy improves survival compared with upfront surgery followed by contemporary adjuvant treatment.

Takeaway

This systematic review and reconstructed individual patient data meta-analysis suggests that neoadjuvant systemic therapy is feasible in selected patients with resectable biliary tract cancer, with a pooled curative-intent resection rate of 71.0%, an intention-to-treat R0 resection rate of 63.6%, and a 3-year OS estimate of 51.0%. However, a substantial proportion of patients did not ultimately undergo curative surgery, and heterogeneity across trials limits interpretation of the pooled outcomes.

The findings support further investigation of neoadjuvant and perioperative treatment strategies, particularly in patients with high-risk disease. Randomized trials comparing these approaches with upfront surgery followed by contemporary adjuvant therapy are needed before neoadjuvant treatment can be recommended routinely for all patients with resectable disease.

The full article is available in Cancer Treatment Reviews.

Find more videos on OncoDaily YouTube TV.

Toma Oganezova
Fact checked by Toma Oganezova MD, Medical Oncologist
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist